Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;172(1):21-45.
doi: 10.1111/imm.13751. Epub 2024 Jan 12.

Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma

Xiu Chen  1   2 , Liqiu Kou  1   2 , Xiaolu Xie  1   2 , Song Su  3 , Jun Li  4 , Yaling Li  1
Affiliations
Free article
Review

Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma

Xiu Chen et al. Immunology. 2024 May.
Free article

Abstract

The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of cancer therapy in recent years, which have changed the landscape of cancer treatment. In the field of HCC treatment, this class of drugs has shown good therapeutic prospects. For example, atezolizumab in combination with bevacizumab has been approved as first-line treatment for advanced HCC due to significant efficacy. However, sensitivity to ICI therapy varies widely among HCC patients. Therefore, there is an urgent need to search for determinants of resistance/sensitivity to ICIs and to screen biomarkers that can predict the efficacy of ICIs. This manuscript reviews the research progress of prognostic biomarkers associated with ICIs in HCC in order to provide a scientific basis for the development of clinically individualised precision medication regimens.

Keywords: biomarkers; hepatocellular carcinoma; immune checkpoint inhibitors; immune‐related adverse events; tumour mutation burden.

PubMed Disclaimer

References

REFERENCES

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
    1. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
    1. Pinto Marques H, Gomes da Silva S, De Martin E, Agopian VG, Martins PN. Emerging biomarkers in HCC patients: current status. Int J Surg. 2020;82S:70–76.
    1. Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol J. 2006;1(2):138–147.
    1. Dal Bello MG, Alama A, Coco S, Vanni I, Grossi F. Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discov Today. 2017;22(8):1266–1273.

Publication types

MeSH terms

Substances

LinkOut - more resources